13F filer · CIK 1336528 ↗
Pershing Square
You are looking at Q2 2016. See the latest, Q1 2026 →
Reported value
$7.51B
−15% on the quarter before
Positions
9
0 new · 0 sold out
Top 10
100.0%
of the value
Est. gain
+$119.4M
on stocks held all quarter
Est. return
+1.6%
on those stocks since Q1 2016
Positions as of Jun 30, 2016, from Pershing Square's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2016. Striped tiles are options.
Largest buys
Since Q1 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
No buys this quarter.
Largest sells
Since Q1 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Zoetis Inc~$980.0MCut · 20.9% → 13.4%−20,649,957 shares
- Canadian Pac Ry Ltd~$528.0MCut · 20.9% → 16.9%−4,100,000 shares
Holdings
As of Jun 30, 2016. Changes are in shares against Mar 31, 2016, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restaurant Brands Intl IncCOM · shares 0% · price +7.1% | 21.7% | $1.63B | +$108.4M | ||||||||
| Canadian Pac Ry LtdCOM · shares −29% · price −2.9% | 16.9% | $1.27B | −$38.4M | ||||||||
| Air Prods & Chems IncCOM · shares 0% · price −1.4% | 14.4% | $1.08B | −$15.3M | ||||||||
| Mondelez Intl IncCL A · shares 0% · price +13.4% | 13.9% | $1.04B | +$123.7M | ||||||||
| Zoetis IncCL A · shares −49% · price +7.1% | 13.4% | $1.00B | +$66.3M | ||||||||
| Valeant Pharmaceuticals IntlCOM · shares 0% · price −23.4% | 5.8% | $434.8M | −$133.0M | ||||||||
| Howard Hughes CorpCOM · shares 0% · price +8.0% | 5.4% | $407.9M | +$30.1M | ||||||||
| Platform Specialty Prods CorCOM · shares 0% · price +3.3% | 5.1% | $379.5M | +$12.0M | ||||||||
| Nomad Hldgs LtdUSD ORD SHS · shares 0% · price −11.4% | 3.5% | $266.0M | −$34.3M | ||||||||
| Total · 9 positions | 100% | $7.51B | +$119.4M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2016 to Q2 2016: 9 stocks held throughout, up $119.4M (+1.6%).
- Mondelez Intl Inc+$123.7M+13%
- Restaurant Brands Intl Inc+$108.4M+7%
- Zoetis Inc+$66.3M+7%
- Howard Hughes Corp+$30.1M+8%
- Platform Specialty Prods Cor+$12.0M+3%
- Air Prods & Chems Inc−$15.3M−1%
- Nomad Hldgs Ltd−$34.3M−11%
- Canadian Pac Ry Ltd−$38.4M−3%
- Valeant Pharmaceuticals Intl−$133.0M−23%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q1 2026 | May 15, 2026 | $13.71B−12% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $15.53B+6% | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | $14.64B+7% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $13.73B+15% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $11.93B−6% | SEC ↗ |
| Q4 2024 | Feb 14, 2025 (amended) | $12.66B−2% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $12.92B+24% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $10.41B−3% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $10.76B+4% | SEC ↗ |
| Q4 2023 | Feb 14, 2024 | $10.40B−1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $10.49B−3% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $10.82B+6% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $10.22B+16% | SEC ↗ |
| Q4 2022 | Feb 10, 2023 | $8.78B+12% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.88B+6% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $7.46B−28% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $10.39B−4% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 (amended) | $10.78B+14% | SEC ↗ |
| Q3 2021 | Nov 15, 2021 | $9.46B−12% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $10.71B+2% | SEC ↗ |
| Q1 2021 | May 17, 2021 | $10.46B+5% | SEC ↗ |
| Q4 2020 | Feb 16, 2021 | $10.00B+13% | SEC ↗ |
| Q3 2020 | Oct 23, 2020 | $8.82B+14% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $7.75B+18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $6.57B+0% | SEC ↗ |
| Q4 2019 | Feb 14, 2020 | $6.55B+1% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 (amended) | $6.49B−3% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $6.71B−0% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $6.72B+13% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $5.96B+14% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $5.21B−10% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $5.80B+20% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $4.83B−18% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $5.87B+15% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $5.11B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $6.01B+1% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $5.96B+1% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $5.91B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $5.41B−28% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $7.51B−15% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $8.85B | SEC ↗ |